Category: Exact Sciences

  • Redefining the approach to cancer care – a mission to improve patient outcomes

    Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million deaths, making cancer the second largest cause of mortality. Although Europe comprises only one eighth of the global population, cancer cases in the region make up a quarter of the world’s total. For a region that often […]

  • Exact Sciences buys cancer detection company Thrive for $2.15 billion

    Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a leader in the cancer-screening market. The Madison-based company has made […]

  • Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

    Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is […]